Klee Justin B. 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Mar 10, 2025
Insider Transaction Report
Form 4
Klee Justin B.
DirectorCo-Chief Executive Officer
Transactions
- Award
Common Stock
2025-03-06+180,118→ 3,376,766 total - Award
Stock Option (right to buy)
2025-03-06+270,177→ 270,177 totalExercise: $3.61Exp: 2035-03-05→ Common Stock (270,177 underlying)
Footnotes (2)
- [F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.